
Publikationsverzeichnis Prof. Dr. med. Birgit Kallinowski

Originalarbeiten

- (1) G. Preclik, **B. Kallinowski**, J. Labenz, F. Lammert
Empfehlungen der Weiterbildungskommission der DGVS: Einheitliche Kriterien für die Erteilung von
Weiterbildungsbefugnissen in der Gastroenterologie

Z Gastroenterol 2016; 54:587-590

- (2) A. Riphaus, T. Wehrmann, J. Hansmann, B. Weber, S. von Delius, M. Jung, P. Tonner, J. Arnold, A.
Behrens, A. Beilenhoff, **B. Kallinowski**, A. Meining, A. Schaible, D. Schilling, H. Seifert, F.
Wappler, I. Kopp
Update S3 Leitlinie: Sedierung in der gastrointestinalen Endoskopie 2014

Z Gastroenterol 2015; 53:802-842

- (3) M. Härter, A. Buchholz, J. Nicolai, K. Reuter, F. Komarahadi, L. Kriston, **B. Kallinowski**, W. Eich,
Ch. Bieber.
Partizipative Entscheidungsfindung und Anwendung von Entscheidungshilfen

DÄB 2015; 112 (40):672-679

- (4) P. Lynen-Jansen, **B. Kallinowski**, J. Labenz, F. Lammert.
Aktuelles aus der Weiterbildungskommission der DGVS: Stand der Revision der
Weiterbildungsordnung

Z Gastroenterol 2014;52:1114-1116

- (5) **B. Kallinowski**, D. Schilling.
Weiterbildung in der Gastroenterologie: quo vadis?

Klinikerarzt 2014; 43(5)256-259

- (6) D.Schilling, K. Leicht, U. Beilenhoff, E. Kern Waechter, **B. Kallinowski**, J. Labenz, C. Weiß, S. Büttner, A. Riphaut.

Impact of S3 training courses „Sedation and emergency management in endoscopy for endoscopy nurses and assisting personnel“ on the process and structure quality in gastroenterological endoscopy in practices and clinics-results of a nationwide survey.

Z Gastroenterol 2013; 51(7): 619-627

- (7) D. Hüppe, E. Zehnter, S. Mauss, K. Böker, T. Lutz, S. Racky, W. Schmidt, J. Ullrich, I. Sbrijer, R. Heyne, A. Schober, C. John, KH. Hey, B. Bokemeyer, **B. Kallinowski**, B. Möller, S. Pape, M. Gutmann, U. Alshuth, C. Niederau.

Epidemiology of chronic hepatitis C in Germany- an analysis of 10326 patients in hepatitis centres and outpatient units.

Z Gastroenterol 2008; 46(1): 34-44

- (8) D. Hüppe, E. Zehnter, S. Mauss, K. Böker, T. Lutz, S. Racky, W. Schmidt, J. Ullrich, I. Brijer, R. Heyne, A. Schober, C. John, K. Hey, B. Bokemeyer, **B. Kallinowski**, B. Möller, S. Pape, M. Tumenn, U. Alshuth, C. Niederau.

Epidemiologie der chronischen Hepatitis C in Deutschland: eine Analyse von 10326 Hepatitis C Infizierten aus Schwerpunktpraxen und -ambulanzen.

Z Gastroenterol 2007;45:1-11

- (9) U. Merle, F. Theilig, E. Fein, S. Gehrke, **B. Kallinowski**, HD. Riedel, S. Bachmann, W. Stremmel, H. Kuaksiz.

Localization of the iron-regulatory proteins hemojuvelin and transferrin receptor 2 to the basolateral membrane domain of hepatocytes.

Histochem Cell Biol. 2007; 127(2): 221-226

- (10) J. Wiegand, B. Buggisch, W. Boecher, S. Zeuzem, CM Gelbmann, T. Berg, W. Kauffmann, **B. Kallinowski**, M. Cornberg, E. Jaeckel, H. Wedemeyer, MP Manns

German HEP-NET Acute HCV Study Group. Early monotherapy with pegylated interferon-alpha-2b for acute hepatitis C infection: the HEP-NET acute -HCV II study.

Hepatology 2006; 43(2):250-256

(11) T. Berg, M. von Wagner, W. Nasser, C. Sarrazin, C. T. Heintges, T. Gerlach, P. Buggisch, T. Goeser, J. Rasenack, GR Pape, WE Schmidt, **B. Kallinowski**, H. Klinker, U. Spengler, P. Martus, U. Alshuth, S. Zeuzem
Extended treatment duration for hepatitis C virus Type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Gastroenterology 2006; 130(4): 1086-1097

(12) B. Kasper, **B. Kallinowski**, T. Herrmann, T. Lehnert, G. Mechttersheimer, T. Geer, AD Ho, G. Egerer
Treatment of Gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.

Dig Dis 2006; (1-2):207-211

(13) F. Nevens, J.N. Zuckermann, A. Burroughs, M.C. Jung, J. Bayas, **B. Kallinowski**, E. Fraga Rivas, C. Duvous, P. Neuhaus, F. Saliba, M. Buti, J. Zarski, F. Pons, C. Vanlemmens, V. Hamitoux, M. Stoffel
Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.

Liver Transpl 2006; 12:1489-1495

(14) Nieters, **B. Kallinowski**, P. Brennan, M. Ott, M. Maynadie, Y Benavente, L. Foretova, PL. Cocco, A. Staines, M. Vornanen, DE. Whitby, P. Boffetta, N. Becker, S. De Sanjose.
Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EpiLymph

Gastroenterology 2006; 131(6): 1879-1886

(15) **B. Kallinowski**
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.

Recent Results Cancer Res 2005;165: 245 -249

(16) C. Veltkamp, R. Sartor, T. Giese, F. Autschbach, I. Kaden, R. Veltkamp, D. Rost, **B. Kallinowski**, W. Stremmel.
Regulatory CD4+/CD25+ cells reverse imbalances in the T cell pool of bone-marrow -transplanted TG(varepsilon) 26 mice leading to the prevention of colitis.

Gut 2005; 54 (2): 207-214

(17)W. Jilg, C. Rink, **B. Kallinowski**
Immunprophylaxe der Hepatitis B

Z Gastroenterol 2004; 42: 698-702

(18)S. Sanjose, A. Nieters, J. Goedert, E Domingo-Domenech, A. de Sevilla, R. Bosch, P. Herrera, A. Domingo, J. Petit, X. Bosch, **B. Kallinowski**
Role of hepatitis C virus infection in malignant lymphoma in Spain.

Int J Cancer 2004; 111: 81-85

(19)H. Kulaksiz, S. Gehrke S, A. Janetzko, D. Rost, T. Bruckner, **B. Kallinowski**, W. Stremmel
Pro-hepcidin: expression and cell-specific localisation in the liver and its regulation in hereditary hemochromatosis, chronic renal insufficiency and renal anemia.

Gut 2004; 53 (5): 735 –743

(20)S. Engler, C. Flechtenmacher, K. Wiedemann, R. Gugler, W. Stremmel, **B. Kallinowski**
Interferon alfa 2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.

J Viral Hep 2004; 11 (1): 60-68

(21)U. Siebert, G. Sroczynski, S. Rossol, J. Wasem, **B. Kallinowski**, U. Ravens-Sieberer, B. Kurth, M. Manns, JG. McHutchison, JB. Wong
German Hepatitis C Model (GEHMO) Group, International Interventional Therapy (IHIT) Group.
Cost effectiveness of peginterferon a-2b plus ribavirin versus interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C.

Gut 2003; 52: 425-432

(22)S. Gehrke, W. Stremmel, I. Mathes, D. Riedel, K. Bents, **B. Kallinowski**
Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.

J Mol Med 2003; 81: 780-787

(23)**B. Kallinowski**, W. Jilg, L. Buchholz, W. Stremmel, S. Engler
Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C.

Z Gastroenterol 2003; 41 (10): 983-990

- (24) L. Schwake, U. Müller, L. Theilmann, W. Stremmel, **B. Kallinowski**
Clinical usefulness and diagnostic value of percutaneous liver biopsy in patients with chronically elevated liver enzymes of non-viral origin.
Z Gastroenterol 2003; 41(4): 303-309
- (25) S. Engler, P. Sauer, E. Klar, W. Stremmel, **B. Kallinowski**
Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin and hepatitis B immunoglobulin.
Transplant Proc 2002; 34 (6):2285-2287
- (26) **B. Kallinowski**, S. Seipp, T. Dengler, E. Klar, L. Theilmann, W. Stremmel
Clinical impact of hepatitis G virus infection in heart and liver transplant recipients.
Transplant Proc 2002;34 (6): 2288-2291
- (27) **B. Kallinowski**, O. Hergesell, M. Zeier
Clinical impact of hepatitis C virus infection in the renal transplant recipient.
Nephron 2002; 91 (4): 541-546
- (28) O. Hergesell, **B. Kallinowski**, M. Wiesel, M. Zeier
Hepatitis C vor und nach Nierentransplantation.
Nieren- und Hochdruckkrankheiten, 2001; 12: 531-541
- (29) S. Engler, P. Sauer, C. Zapletal, M. Golling, E. Klar, C. Benz, W. Stremmel, **B. Kallinowski**
Immunogenicity of two accelerated hepatitis B-vaccination protocols in liver transplant candidates.
Europ J Gastroenterol Hepatol 2001; 13: 363-367
- (30) **B. Kallinowski**, H. Liehr, B. Moeller, W. Stremmel, JG. Wechsler, M. Wiese T. Goeser
Combination therapy with interferon a-2b and ribavirin for the treatment of relapse patients and nonresponders with chronic HCV infection.
Z Gastroenterol 2001; 39: 199-206

- (31) G. Teuber, HF Lohr, **B. Kallinowski**, T. Berg, R. Müller, S. Zeuzem
Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B.
Dtsch Med Wochenschr 2001;126 (5): 97-102
- (32) J. Pohl, W. Stremmel, **B. Kallinowski**
Pulmonale Sarkoidose: eine seltene Nebenwirkung einer Interferon- α Therapie bei chronischer Hepatitis C Infektion.
Z Gastroenterol 2000; 38: 951-955
- (33) J. Pohl, T. Hess, W. Hofmann, W. Stremmel, **B. Kallinowski**
Spontaneous regression of intrahepatic lesions mimicking metastatic disease.
Z Gastroenterol 2000; 38: 803 - 806
- (34) **B. Kallinowski**, A. Knöll, E. Lindner, R. Sängler, W. Stremmel, J. Vollmar, B. Zieger, W. Jilg
Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary seroconversion course?
Vaccine 2000;19:16-22
- (35) **B. Kallinowski**, S. Scherer, A. Mehrabi, L. Theilmann, W. Stremmel
Clinical impact of HLA DRB1 genotypes in chronic hepatitis C virus (HCV) infection.
Transplant Proceed 1999;31:3346-3349
- (36) **B. Kallinowski**, M. Janicki, R. Seelig, S. Seipp, T. Dengler, P. Schnitzler, L. Theilmann, W. Stremmel
Clinical impact of GBV-C infection after heart transplantation (HTX).
J Heart Lung Transplant 1999 ;18: 190-193
- (37) S. Seipp, M. Scheidel, W. Hofmann, U. Töx, L. Theilmann, T. Goeser, **B. Kallinowski**
Hepatotropism of GB virus (GBV-C): GBV-C replication in human hepatocytes and cells of human hepatoma cell lines.
J Hepatol 1999;30: 570 -579

(38) S. Gehrke, I. Henrich, J. Mytilineos, H. Riedel, T. Herrmann, **B. Kallinowski**, W. Stremmel.
Mutationen des Hämochromatosegens HFE.

Verdauungskrankheiten 1998; (5): 223 -229

(39) S. Seipp, T. Goeser, L. Theilmann, **B. Kallinowski**
Establishment of a highly specific detection system for GB virus C (GBV-C) minus strand RNA.

Virus Research 1998; 56: 183 – 189

(40) **B. Kallinowski**, C. Benz, L. Buchholz, W. Stremmel
Accelerated schedule of hepatitis B vaccination in liver transplant candidates.

Transplant Proc. 1998; 30: 797 -799

(41) **B. Kallinowski**, R. Ahmadi, S. Seipp, H.M. Müller, T. Goeser, J. Bommer, W. Stremmel
Clinical impact of GB-C virus in hemodialysis patients.

Nephrol Dial Transplant 1998;13: 93 -98

(42) **B. Kallinowski**, C. Buhrmann, S. Seipp, T. Goeser, W. Stremmel, G. Otto, L. Theilmann
Incidence, prevalence and clinical outcome of GBV-C infection in liver transplant patients.

Liver Transplant Surg 1998; 4: 28 -33

(43) **B. Kallinowski**, K. Haseroth, G. Marinos, W. Stremmel, L. Theilmann, M.V. Singer, S. Rossol
Induction of TNF- α and TNF receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection.

Clin Exp Immunol 1998;111: 269 – 277

(44) M. Möhler, F. Gutzler, **B. Kallinowski**, T. Goeser, W. Stremmel
Primary hepatic high-grade Non-Hodgkins's Lymphoma and chronic hepatitis C infection.

Dig Dis Sci, 1997, 42: 2241 – 2245

(45) **B. Kallinowski**, W. Stremmel
Prävention viraler Hepatitiden: neue und bekannte Impfstoffe.

Klinikerarzt 1997;6 (26): 150 - 155

- (46) **B. Kallinowski**, S. Seipp, S. Fatehi, U. Sommerfeld, K. Andrassy, W. Stremmel, L. Theilmann
Significance of hepatitis, B, hepatitis C and GBV-C in ANCA-positive hemodialysis patients.
Nephron 1997;77: 357 – 358
- (47) **B. Kallinowski**, H.L. Bock, R. Clemens, L. Theilmann
Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: first results.
Liver 1996;16: 271 - 273
- (48) L. Theilmann, C. Solbach, U. Töx, **B. Kallinowski**, T. Goeser
Bedeutung der Hepatitis -C- Virus-Genotypisierung.
Münch Med Wschr. 1995; (137) 44: 699 -701
- (49) **B. Kallinowski**, H.L. Bock, R. Clemens, L. Theilmann
Immunogenität und Verträglichkeit eines kombinierten Hepatitis A/B Impfstoffes: erste Ergebnisse mit einer Kandidatvakzine.
Dtsch Med Wschr 1995; 120: 1426 – 1429
- (50) H.J. Arnold, B. Heilig, **B. Kallinowski**, G. Otto, B. Kommerell, L. Theilmann
Soluble tumor necrosis factor receptors in patients with recurrent hepatitis C virus infection after liver transplantation.
J Clin Invest 1994; 72 (194): 470
- (51) **B. Kallinowski**, W. Nöldge, A. Stiehl
Crohn's disease with Behcet's syndrome like appearance: a case report.
Z Gastroenterol 1994;32: 642 – 644
- (52) H. M. Müller, **B. Kallinowski**, C. Solbach, L. Theilmann, T. Goeser, E. Pfaff
B-lymphocytes are predominantly involved in viral propagation of hepatitis C virus (HCV).
Arch Virol (Suppl). 1994; 9: 307 – 316
- (53) **B. Kallinowski**, H. M. Müller, Ch. Solbach, T. Goeser, D. Kabelitz, L. Theilmann
Hepatitis C virus RNA in different blood lymphocyte subsets.
Eur J Gastroenterol Hepatol 1994, 6: 249 – 252

- (54) H.M. Müller, E. Pfaff, T. Goeser, **B. Kallinowski**, C. Solbach, L. Theilmann
Peripheral blood leukocytes serve as a possible extrahepatic site for viral replication.
J Gen Virol 1993;74: 669 - 674
- (55) **B. Kallinowski**, L. Theilmann
Die Hepatitis C: eine Übersicht über Klinik, Diagnostik, Therapie und Prävention.
Krankenpflegejournal 1993;31: 38 – 40
- (56) K. Gmelin, F. Kurzen, **B. Kallinowski**, T. Goeser, J. Arnold, B. Kommerell, L. Theilmann
Follow-up of patients with hepatitis non-A, non-B: incidence and persistence of anti-HCV depend on route of transmission.
Arch Virol 1992 (Suppl) 4: 222 – 2224
- (57) **B. Kallinowski**, L. Theilmann, K. Gmelin, B. Kommerell, F. Hofmann, N. Scheiermann, B. Wohland, H. Stickl, H. Maiwald, K. Moriabadi, H. L. Bock, R. Clemens
Immunogenität, Verträglichkeit und Konsistenz eines inaktivierten Hepatitis-A-Impfstoffes: eine randomisierte, kontrollierte Multicenterstudie mit drei konsekutiven Impfstoffchargen.
Inn Med 1992; 2: 41 – 44
- (58) L. Theilmann, **B. Kallinowski**, K. Gmelin, F. Hofmann, N. Scheiermann, B. Wohland, H. Stickl, H. Maiwald, K. Moriabadi, H.L. Bock, R. Clemens, A. Safary, F. E. Andre
Reactogenicity, and immunogenicity of three different lots of a hepatitis A vaccine.
Vaccine 1992;10 (Suppl. 1): 132 – 134
- (59) **B. Kallinowski**, K. Gmelin, B. Kommerell, H.L. Bock, R. Clemens, N. Scheiermann, B. Wohland, F. Hofmann, L. Theilmann
Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine - a randomized multicentre study with three consecutive vaccine lots.
Vaccine 1992; 10 (8) : 500 – 501
- (60) **B. Kallinowski**, B. Aulmann, B. Kommerell, L. Theilmann
Hepatitis A: ein up-date.
Klinikerarzt 1992; 21 (8) : 381 – 389

(61)L. Theilmann, K. Gmelin, **B. Kallinowski**, B. Kommerell, J. Koderisch, K. Andrassy
Prevalence of antibodies to hepatitis C virus in sera from patients with systemic necrotizing vasculitis.

Nephron 1991; 57: 482

(62)**B. Kallinowski**, W. J. Hofmann , K. Gmelin , U. Töx , B. Kommerell , L. Theilmann
Therapie der chronischen Hepatitis C und Non-A Non-B mit a-Interferon.

Inn Med 1991, 4: 80 – 83

(63)**B. Kallinowski**, L. Theilmann, K. Gmelin, K. Andrassy, D. Deppermann, B. Weinel, B. Kommerell
Prevalence of antibodies to hepatitis C virus in hemodialysis patients.

Nephron 1991;59: 236 – 238

(64)**B. Kallinowski**, L. Theilmann, K. Gmelin, M. Rambausek, M. Möhring, B. Kommerell
Incidence and prevalence of antibodies to hepatitis C virus in kidney transplant patients.

J Hepatol 1991;13 : 404 – 405

(65)**B. Kallinowski**, L. Theilmann, R. Zimmermann , E. Gams , B. Kommerell , A. Stiehl
Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid.

Transplantation 1991;51 (5) : 1128 – 1129